Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.58 AUD 4.5% Market Closed
Market Cap: 167.7m AUD

Net Margin
Recce Pharmaceuticals Ltd

-278.1%
Current
-298%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-278.1%
=
Net Income
-21.4m
/
Revenue
7.7m

Net Margin Across Competitors

No Stocks Found

Recce Pharmaceuticals Ltd
Glance View

Market Cap
167.3m AUD
Industry
Pharmaceuticals

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.

RCE Intrinsic Value
0.5 AUD
Overvaluation 13%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-278.1%
=
Net Income
-21.4m
/
Revenue
7.7m
What is the Net Margin of Recce Pharmaceuticals Ltd?

Based on Recce Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of -278.1%.

Back to Top